A cell or gene therapy trial does not run like a typical drug study where a manufactured product is shipped to a site and administered on a set schedule. For autologous therapies especially, the “product” often starts as a patient’s own cells, travels to a manufacturing facility, and returns to that same patient weeks later — a process that introduces operational requirements most conventional trials never have to manage.
Why CGT Trials Demand a Different Operating Model
Because of this patient-specific manufacturing process, sponsors running cell and gene therapy programs generally look for a partner whose operational experience extends beyond general clinical trial management. Tigermed describes its cell and gene therapy services group as drawing on more than 100 key opinion leader resources and over 200 professional CGT strategic cooperation centers, and reports having supported more than 170 CGT clinical studies overall, including more than 50 stem cell studies and over 150 gene therapy studies.
This kind of specialized structure matters early in a program, sinceCGT programs typically require early coordination across CMC planning, product-specific preclinical considerations, and clinical operations design well before the first patient undergoes cell collection — decisions that a generalist clinical operations team may not be equipped to make without dedicated CGT experience.
Patient Identification and Leukapheresis Logistics
For autologous therapies such as CAR-T products, the process begins with leukapheresis — a procedure that circulates a patient’s blood through a machine to collect specific white blood cells, typically lymphocytes, while returning the remaining blood components to the patient over several hours. This step generally needs to be coordinated with the manufacturing site’s production capacity and scheduling requirements, because a mismatch between collection timing and manufacturing availability can delay subsequent processing.
Leukapheresis capacity can be an important site-selection consideration, particularly where access to appropriately equipped collection centers is limited or scheduling capacity is constrained. Sponsors are generally advised to confirm a site’s apheresis capacity and its coordination process with the manufacturing facility before finalizing site selection for an autologous CGT trial, rather than assuming general oncology or infusion capability is sufficient.
Maintaining Product Identity From Collection to Infusion
Autologous cell therapy introduces a requirement that most conventional trials do not face: the manufactured product has to be verifiably matched back to the same patient whose cells were originally collected. Unlike many conventional investigational products that can be dispensed from an approved batch to eligible patients, an autologous CAR-T product is linked to the individual patient whose cells were collected and therefore requires controls to maintain that identity throughout manufacturing and return for administration.
This requirement means tracking systems for autologous CGT products generally need to verify patient-product matching at multiple points — collection, shipment to the manufacturing site, processing, and the return shipment for infusion — in addition to the more standard documentation of storage conditions and handling history. A single identification or labeling error at any of these points carries consequences well beyond a typical sample handling mistake.
Managing Vein-to-Vein Time
The interval between a patient’s leukapheresis collection and the eventual infusion of their manufactured product is generally referred to as vein-to-vein time. Real-world data from patients with relapsed or refractory large B-cell lymphoma treated with axicabtagene ciloleucel have found that longer vein-to-vein times were associated with lower complete response rates and worse overall survival after adjustment for other prognostic factors, although the observational design does not establish that V2V time alone caused these differences — while manufacturing time itself for that product has been reported at around 18 days on average, suggesting that delays elsewhere in the process, such as scheduling gaps or bridging therapy needs, can contribute more to overall vein-to-vein time than manufacturing itself.
For trial operations, this means vein-to-vein time is not simply a manufacturing metric to monitor after the fact — it depends on how well apheresis scheduling, product shipment, manufacturing slot availability, and return shipment are coordinated across multiple parties before a patient’s collection ever begins. A CRO managing this kind of trial generally needs visibility across each of these steps rather than only the clinical site’s portion of the process.
Designing Long-Term Follow-Up for Gene Therapy Products
Because some gene therapy products are designed to produce permanent or long-lasting genetic changes, regulatory expectations for patient monitoring extend well beyond a typical trial’s active follow-up period. The FDA’s January 2020 LTFU guidance recommends a risk-based approach to follow-up duration, with observation periods of up to 15 years for certain integrating-vector and genome-editing products and up to 5 years for AAV vector products, depending on product- and patient-specific risk factors. The guidance also recommends more frequent testing intervals, generally every 6 months or less, during the first 5 years of observation.
Designing a protocol to support this kind of extended monitoring window introduces its own operational challenges, since maintaining contact with patients, sites, and investigators over an extended LTFU period requires retention and data-collection processes that may differ substantially from those used during a typical short-term clinical tria. Sponsors are generally advised to plan LTFU logistics — including how patient contact will be maintained if a treating site closes or an investigator leaves during the observation period — as part of the original protocol design rather than as an afterthought once the active trial phase concludes.
Bringing These Requirements Together
Each of these operational elements — apheresis coordination, product identity verification, vein-to-vein time management, and long-term follow-up design — interacts with the others rather than functioning independently. A delay in apheresis scheduling extends vein-to-vein time, and a long-term follow-up plan is only as strong as the patient identification and contact systems established at the start of the trial.
Companies such as Tigermed, which describe an integrated CGT service model spanning preclinical considerations, CMC, regulatory support, and clinical development alongside a network of strategic cooperation centers, illustrate one approach to coordinating these interconnected requirements, illustrate one approach to coordinating these interconnected requirements under a single cell and gene therapy clinical trials program. As with any specialized therapeutic area, sponsors are advised to confirm a partner’s specific experience with their vector type and manufacturing model before finalizing a selection.
